Avadel Pharmaceuticals plc (NASDAQ:AVDL) has a beta value of 1.48 and has seen 1.04 million shares traded in the last trading session. The company, currently valued at $927.74M, closed the last trade at $9.59 per share which meant it gained $0.2 on the day or 2.13% during that session. The AVDL stock price is -82.59% off its 52-week high price of $17.51 and 33.47% above the 52-week low of $6.38.
The consensus among analysts is that Avadel Pharmaceuticals plc (AVDL) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 8 have rated it as a Hold, with 8 advising it as a Buy. 0 have rated the stock as Underweight.
Avadel Pharmaceuticals plc (NASDAQ:AVDL) trade information
Sporting 2.13% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the AVDL stock price touched $9.59 or saw a rise of 3.91%. Year-to-date, Avadel Pharmaceuticals plc shares have moved -8.75%, while the 5-day performance has seen it change 6.08%. Over the past 30 days, the shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL) have changed 34.50%.
Wall Street analysts have a consensus price target for the stock at $20, which means that the shares’ value could jump 52.05% from current levels. The projected low price target is $19.0 while the price target rests at a high of $21.0. In that case, then, we find that the current price level is -118.98% off the targeted high while a plunge would see the stock gain -98.12% from current levels.
Avadel Pharmaceuticals plc (AVDL) estimates and forecasts
The company’s shares have lost -37.32% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 10.39% over the past 5 years.
AVDL Dividends
Avadel Pharmaceuticals plc is expected to release its next earnings report in June this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Avadel Pharmaceuticals plc (NASDAQ:AVDL)’s Major holders
The top two institutional holders are JANUS HENDERSON GROUP PLC with over 13.3 million shares worth more than $187.06 million. As of 2024-06-30, JANUS HENDERSON GROUP PLC held 13.8296% of shares outstanding.
The other major institutional holder is POLAR CAPITAL HOLDINGS PLC, with the holding of over 6.56 million shares as of 2024-06-30. The firm’s total holdings are worth over $92.24 million and represent 6.823% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund . As of Dec 31, 2024 , the former fund manager holds about 2.91% shares in the company for having 2.81 shares of worth $26.98 million while later fund manager owns 2.48 shares of worth $23.8 million as of Mar 31, 2025 , which makes it owner of about 2.57% of company’s outstanding stock.
